<DOC>
	<DOCNO>NCT00004213</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness 3-aminopyridine-2-carboxaldehyde thiosemicarbazone treat patient solid tumor respond previous treatment .</brief_summary>
	<brief_title>3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine effect 3-aminopyridine-2-carboxaldehyde thiosemicarbazone ( 3-AP ) patient solid tumor evaluate safety tolerability , maximum tolerate dose ( MTD ) recommend dose Phase II study , pharmacokinetics , tumor response . OUTLINE : This dose escalation study . Patients receive 3-aminopyridine-2-carboxaldehyde thiosemicarbazone ( 3-AP ) IV 2 hour day 1-5 . Treatment repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 1-6 patient receive escalate dos 3-AP maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow 4 week recover . PROJECTED ACCRUAL : Approximately 21 patient accrue study .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant solid tumor fail 1 conventional treatment unlikely respond currently available therapy No active CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 3 month Hematopoietic : WBC great 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count great 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 2.0 mg/dL AST ALT great 3 time upper limit normal ( ULN ) Alkaline phosphate great 3 time ULN ( great 5 time ULN liver metastasis present ) Renal : Creatinine le 2.0 mg/dL Cardiovascular : No myocardial infarction within past 3 month No symptomatic coronary artery disease heart block No uncontrolled congestive heart failure Pulmonary : No moderate severe pulmonary dysfunction Other : Not pregnant nursing Negative pregnancy test Fertile woman must use effective contraception Body weight great 50 kg No active infection No mental deficit and/or psychiatric disorder would preclude study No lifethreatening illness No bleed disorder ( except occult blood gastrointestinal cancer ) PRIOR CONCURRENT THERAPY : Biologic therapy : Prior growth factor treatment allow blood count normal Chemotherapy : At least 3 week since prior chemotherapy recover At least 6 week since prior nitrosoureas mitomycin recover Prior hydroxyurea allow recovered Endocrine therapy : At least 2 week since prior hormonal therapy Radiotherapy : At least 3 week since prior radiotherapy recover No prior radiotherapy great 30 % bone marrow Surgery : At least 2 week since prior major surgery Other : At least 4 week since prior investigational agent recover No concurrent investigational agent without consent sponsor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>